Quantcast
Last updated on April 17, 2014 at 14:57 EDT

Latest Novartis AG Stories

2010-12-22 15:05:00

EAST HANOVER, N.J., Dec. 22, 2010 /PRNewswire/ -- Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ). The FDA approval was based on data from a double-blind,...

2010-12-06 10:40:00

EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- The Novartis Pharmaceutical Corporation ("Novartis") oral investigational drug LBH589 (panobinostat) demonstrated substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients who had relapsed or had become refractory after an autologous stem cell transplant, according to new data from a Phase II clinical trial presented today(1). In this pivotal single-arm study, one of the largest ever conducted in...

2010-12-06 06:09:00

EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the disease 24-month analysis confirms Tasigna induces deeper and more durable cytogenetic and molecular responses Tasigna now approved in the US and Switzerland for this indication; regulatory submissions under review in EU, Japan and other countries worldwide Novartis announced today 24-month...

2010-12-03 18:09:00

EAST HANOVER, N.J., Dec. 3, 2010 /PRNewswire/ -- A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa® (zoledronic acid) significantly improved overall survival (OS) and progression-free survival (PFS) in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events...

2010-12-01 00:04:00

EAST HANOVER, N.J., Dec. 1, 2010 /PRNewswire/ -- With more than 170 presentations focused on its marketed and pipeline compounds at key oncology medical congresses in December, Novartis continues to demonstrate progress of its innovative research and development efforts, collaboration with the scientific community and commitment to patients with cancer and rare diseases(1,2). The American Society of Hematology (ASH) annual meeting in Orlando, FL (December 4-7) will feature 30 oral...

b7bc62dffd258f9db4937b526bef450d1
2010-11-09 12:45:00

Novartis AG is trying to receive regulatory approval within 18 months for a tablet that contains an embedded microchip. The program will use the Swiss firm's established drugs taken by transplant patients to avoid organ rejection.  However, Trevor Mundel, head of global development, believes the concept can be applied to many other pills. "We are taking forward this transplant drug with a chip and we hope within the next 18 months to have something that we will be able to submit to the...

2010-11-03 16:08:00

EAST HANOVER, N.J., Nov. 3, 2010 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS)(1,2). This study, which was previously presented at the 46th American Society of Clinical Oncology annual meeting, is the first prospective clinical...

2010-10-27 15:37:00

PRINCETON, N.J., Oct. 27 /PRNewswire/ -- Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number...

2010-10-27 09:44:00

CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Novartis announced today that it will add 300 new jobs and invest $600 million over the next five years to expand its global Research headquarters campus on Massachusetts Avenue in Cambridge, Mass. "Novartis was the first global pharmaceutical company to move its Research headquarters to Massachusetts just a few years ago. It has achieved prominence and, we believe, helped to amplify Cambridge's magnetism for others in the biomedical field to...

2010-10-16 15:45:00

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.(1) The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada. The study showed that Reclast maintained bone mass in...